What question did this study set out to answer?

Determine the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced colorectal cancer (CRC) patients.

Effect of hyperthermic intraperitoneal chemotherapy on patients with advanced colorectal cancer: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

A systematic review reveals that HIPEC improves survival in advanced colorectal cancer, indicating potential benefits and risks.

Determine the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced colorectal cancer (CRC) patients.
Conducted a systematic review and meta-analysis of studies up to April 2024.
Included 10 cohort studies and 4 randomized controlled trials with 2851 patients.
Analyzed data using Stata/MP 17.0 software to compare overall survival and disease-free survival.
HIPEC improved 1-year disease-free survival (OR = 1.64) and 5-year overall survival (OR = 1.49) rates.
Reduced overall peritoneal metastasis rate (OR = 0.66).
For advanced high-risk CRC without prior metastases, HIPEC had a preventive effect on peritoneal metastases (OR = 0.71).
Increased complications included thrombopenia (OR = 5.77) and neutropenia (OR = 3.21).

Su et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark